AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lake Street Reiterates Buy Rating on InspireMD with $5 Price Target
ByAinvest
Thursday, Jul 10, 2025 4:52 am ET1min read
Lake Street maintains a Buy rating for InspireMD with a $5.00 price target. The company's shares closed at $2.26. Analyst Frank Takkinen has a 37.54% success rate on recommended stocks and a Moderate Buy consensus with a $4.50 price target. InspireMD has a market cap of $68.01M and a P/E ratio of -2.84.
InspireMD Inc (NASDAQ:NSPR) has seen its stock price fluctuate, with shares closing at $2.26 on July 2, 2025. The company, which focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases, has received various analyst ratings and price targets.Lake Street maintains a Buy rating for InspireMD with a $5.00 price target [1]. Analyst Frank Takkinen, who has a 37.54% success rate on recommended stocks, has a Moderate Buy consensus with a $4.50 price target [2]. InspireMD has a market cap of $68.01M and a P/E ratio of -2.84, indicating a significant undervaluation compared to its peers.
InspireMD's recent news includes the commercial launch of its CGuard Prime carotid stent system in the United States, following FDA approval [3]. The company also announced the appointment of Michael Lawless as its new CFO [4]. These developments have driven a 4% increase in pre-market trading, suggesting investor optimism.
Despite the recent positive news, InspireMD's stock price has been volatile, with a 52-week range of $1.99 to $3.798. The company's net income was -$36.139, and its EPS was -$0.79, indicating financial challenges. However, the company holds more cash than debt on its balance sheet, providing some financial stability.
In conclusion, InspireMD Inc's stock presents both risks and opportunities for investors. With analyst ratings suggesting a potential upside, investors should carefully consider the company's financial health and recent developments before making investment decisions.
References:
[1] https://www.investing.com/equities/inspiremd-inc
[2] https://www.investing.com/equities/inspiremd-inc
[3] https://www.investing.com/news/inspiremd-stock-rises-after-us-commercial-launch-of-carotid-stent-system-2635453
[4] https://www.investing.com/news/inspiremd-names-michael-lawless-as-new-cfo-2635454
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet